|
Lymphoma
|
0.010 |
GeneticVariation
|
group |
BEFREE |
<i>HCP5</i> rs3099844 was associated with anti-SSA (<i>P</i> = 0.006, OR = 3.07) and anti-SSB (<i>P</i> = 0.005, OR = 2.66) antibodies, severity of focus score (<i>P</i> = 0.03, OR = 12), and lymphoma development (<i>P</i> = 0.002, OR = 7.23).
|
30882006 |
2019 |
|
Adult Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
<i>HCP5</i> rs3099844 was associated with anti-SSA (<i>P</i> = 0.006, OR = 3.07) and anti-SSB (<i>P</i> = 0.005, OR = 2.66) antibodies, severity of focus score (<i>P</i> = 0.03, OR = 12), and lymphoma development (<i>P</i> = 0.002, OR = 7.23).
|
30882006 |
2019 |
|
Childhood Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
<i>HCP5</i> rs3099844 was associated with anti-SSA (<i>P</i> = 0.006, OR = 3.07) and anti-SSB (<i>P</i> = 0.005, OR = 2.66) antibodies, severity of focus score (<i>P</i> = 0.03, OR = 12), and lymphoma development (<i>P</i> = 0.002, OR = 7.23).
|
30882006 |
2019 |
|
Neoplasm Metastasis
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
<i>SHISA3</i> suppressed NPC cell invasion and metastasis <i>in vitro</i> and <i>in vivo</i> by impeding the E3 ubiquitin ligase tripartite motif containing 21 (TRIM21)-mediated ubiquitination and degradation small G protein signaling modulator 1 (SGSM1) and by inhibiting the MAPK pathway activation.
|
30573520 |
2019 |
|
Serrated polyp
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
(2) Proximal SDR (PSDR) meaning colonoscopies with any serrated polyp (SSA/P, HP, TSA) of any size proximal to the sigmoid colon divided by the total number of screening and surveillance colonoscopies, respectively.
|
28153571 |
2017 |
|
Neuroendocrine Tumors
|
0.020 |
AlteredExpression
|
group |
BEFREE |
5-HIAA = 5-hydroxyindoleacetic acid; CgA = chromogranin A; CI = confidence interval; CLARINET = Controlled Study of Lanreotide Antiproliferative Response in Neuroendocrine Tumors; CS = carcinoid syndrome; ELECT = Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment; HR = hazard ratio; ITT = intention-to-treat; NET = neuroendocrine tumor; PanNET = pancreatic NET; PFS = progression-free survival; PPI = proton pump inhibitor; SSA = somatostatin analogue; ULN = upper limit of normal.
|
30084687 |
2018 |
|
Sjogren's Syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
70 patients with anti-SSA antibody positive SS were selected as the observation group, and the non-positive Sjogren syndrome (PSS) subjects were collected as the control group at the same time.
|
30070316 |
2018 |
|
Neonatal Systemic lupus erythematosus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neonatal lupus erythematosus (NLE) is an inflammatory syndrome in the fetus or neonate associated with the presence of anti-Ro(SSA) and anti-La(SSB) antibodies in the mother.
|
10743829 |
2000 |
|
Neonatal Systemic lupus erythematosus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neonatal lupus erythematosus (NLE) is a rare disease characterized by the transplacental passage from the mother to the fetus of autoantibodies, in particular anti-Ro(SS-A), anti-La(SS-B), or both.
|
10879307 |
2000 |
|
Neonatal Systemic lupus erythematosus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neonatal lupus erythematosus is an immune-mediated disease associated with the transplacental passage of maternal autoantibodies, primarily anti-Ro (SS-A) and anti-La (SS-B).
|
12542254 |
2002 |
|
Neonatal Systemic lupus erythematosus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neonatal lupus is linked to the presence of anti-Ro/SS-A and anti-La/SS-B antibodies in the mother, although other factors probably of fetal origin are important.
|
17153854 |
2006 |
|
Lupus Erythematosus, Subacute Cutaneous
|
0.030 |
Biomarker
|
disease |
BEFREE |
Subacute cutaneous lupus erythematosus (SCLE) is a photosensitive form of lupus-specific skin lesion that is strongly associated with the presence of anti-Ro/SSA autoantibody.
|
18540991 |
2008 |
|
Hyperplastic Polyp
|
0.100 |
Biomarker
|
disease |
BEFREE |
Hyperplastic polyps (HPs) share some histologic and molecular characteristics with SSA/P, but it is unclear whether SSA/Ps are derived from HPs or whether they develop by a different pathogenetic pathway.
|
21836485 |
2011 |
|
Serrated hyperplastic polyposis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Serrated (hyperplastic) polyposis (SP) is a rare disorder with multiple colorectal hyperplastic polyps and often sessile serrated adenomas/polyps (SSA/P) or adenomas.
|
22490521 |
2013 |
|
Primary Sjögren's syndrome
|
0.100 |
Biomarker
|
disease |
BEFREE |
Primary Sjögren's syndrome (SS) is a systemic autoimmune inflammatory disease characterized by focal lymphocytic infiltrates in the lachrymal and salivary glands and autoantibodies against the SSA/Ro and SSB/La antigens.
|
23944604 |
2013 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sessile serrated adenoma/polyp (SSA/P) is considered as an early precursor in the serrated neoplasia pathway leading to colorectal cancer development.
|
24925057 |
2015 |
|
Trichohepatoenteric Syndrome
|
0.020 |
Biomarker
|
disease |
BEFREE |
The syndrome is believed to be caused by transplacental passage of an IgG antibody, usually the anti-Ro (SS-A) antibody, from the mother to the infant.
|
2579661 |
1985 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sessile serrated adenoma/polyp (SSA/P) is a colorectal polyp that has malignant potential.
|
27663716 |
2017 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sessile serrated adenoma/polyps (SSA/P) are premalignant lesions of colorectal cancer that are difficult to distinguish histologically from hyperplastic polyps (HP) of minimal to no malignant potential.
|
27705923 |
2017 |
|
Congenital heart block
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Congenital complete heart block (CCHB) occurs in the offspring of mothers who have the HLA-A1;B8; DR3 haplotype and Ro (SS-A) autoantibodies.
|
2818659 |
1989 |
|
Neonatal Systemic lupus erythematosus
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neonatal lupus: Follow-up in infants with anti-SSA/Ro antibodies and review of the literature.
|
28212920 |
2017 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sessile serrated adenoma/polyp (SSA/P) was a risk factor for VMX/+ margin in CSP specimens (OR 58.36, 95% CI 7.45-456.96, p < 0.001).
|
29516270 |
2018 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sessile serrated adenoma/polyp (SSA/P) is regarded as a genetically homogeneous entity, with most lesions harbouring the BRAF V600E mutation.
|
29920740 |
2018 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Sessile serrated adenoma/polyp (SSA/p) is a premalignant lesion in the colon and rectum.
|
30510949 |
2018 |
|
Sessile Serrated Adenoma/Polyp
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sessile serrated adenoma/polyps (SSA/P) are recognized as precancerous lesions in the colon and resemble hyperplastic polyps (HP).
|
30693669 |
2019 |